DEALS: Qiagen buys key assets


Qiagen buys key assets


DEALS

WHO

WITH

WHAT

SCOOP

Altana

Eckhart

$768 million buyout

Once the deal is complete, Altana will add Eckhart's chemicals and pigments unit to its chemicals division and spin the venture off as a separate company.

Qiagen

SuNyx

asset buyout

Qiagen buys technology that examines sample preparation by leveraging unique, nanotechnology-based surface structures.

Qiagen

LumiCyte

asset buyout

LumiCyte has been developing capability that dramatically increases the limits of detection achievable through mass spectroscopy.

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.